| Literature DB >> 32595518 |
Marco Antônio R Da Silva1,2, Liliana C Baptista3, Rafael S Neves1, Elias De França4, Helena Loureiro1,5, Fabio Santos Lira6, Erico C Caperuto4, Manuel T Veríssimo1, Raul A Martins1.
Abstract
To date, there are several knowledge gaps on how to properly prescribe concurrent training to achieve the best dose-response, especially regarding the optimal intensity or volume of the aerobic component. Thus, the objective of this study is to analyze the effects of different aerobic exercise modes and intensities [i.e. aerobic high-intensity interval training (HIIT) versus moderate-intensity continuous aerobic training (MICT) combined with a resistance training (RT) program] on metabolic outcomes in participants with metabolic syndrome (MetS). Thirty-nine men and women (67.0 ± 6.7 years) volunteered to a 12-weeks exercise intervention (3 week-1, 50 min/session) and were randomly assigned to one of three groups: (a) RT plus MICT (RT+MICT) (2 males; 11 females); (b) RT plus HIIT (RT+HIIT) (4 males; 9 females); and (c) control group (CON) - without formal exercise (4 males; 9 females). Intensity was established between 60 and 70% of maximum heart rate (HRmax) in RT+MICT and ranged from 55-65% to 80-90% HRmax in the RT+HIIT group. Dependent outcomes included morphological, metabolic and hemodynamic variables. Both training groups improved waist circumference (RT+MICT: P = 0.019; RT+HIIT: P = 0.003), but not body weight, fat mass or fat-free mass (P ≥ 0.114). RT+HIIT group improved fasting glucose (P = 0.014), low density lipoprotein [LDL (P = 0.022)], insulin (P = 0.034) and homeostatic model assessment (P = 0.028). RT+MICT group reduced triglycerides (P = 0.053). Both exercise interventions did not change high sensitivity C-reactive protein, glycated hemoglobin, high density lipoprotein and total cholesterol, systolic, diastolic or mean arterial blood pressure (P ≥ 0.05). The CON group reduced the LDL (P = 0.031). This trial suggests that short-term exercise mode and intensity may differently impact the metabolic profile of individuals with MetS. Further, our data suggests that both concurrent trainings promote important cardiometabolic gains, particularly in the RT+HIIT. Nonetheless, due to the small-to-moderate effect size and the short-term intervention length, our data suggests that the intervention length also has an important modulating role in these benefits in older adults with MetS. Therefore, more research is needed to confirm our results using longer exercise interventions and larger groups.Entities:
Keywords: age groups; endurance training; high-intensity interval training; metabolic syndrome; resistance training
Year: 2020 PMID: 32595518 PMCID: PMC7300209 DOI: 10.3389/fphys.2020.00572
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
FIGURE 1Cohort flux diagram.
Demographic and clinical characteristics of participant’s at baseline and comparison between groups calculated from a MANOVA controlling for the effect of sex and age.
| RT+MICT ( | RT+HIIT ( | CON ( | ||
| Women, | 11(85%) | 9(69%) | 9(69%) | 0.584# |
| Age, years | 71.1(4.8) | 67.4(3.9) | ||
| Body mass, kg | 70.5(14.6) | 77.9(17.4) | 76.1(9.3) | 0.596 |
| BMI, kg/m2 | 29.3(5.5) | 31.1(5.5) | 29.5(3.2) | 0.633 |
| WC, cm | 98.2(11.5) | 102.5(14.7) | 99.8(9.0) | 0.788 |
| VO2peak, mL/kg–1/min–1 | 19.7(3.9) | 21.4(4.0) | 20.5(3.3) | 0.577 |
| Fat mass, % | 38.6(4.6) | 39.5(7.3) | 38.2(6.2) | 0.554 |
| Fat mass, Kg | 27.3(7.2) | 31.0(11.2) | 28.6(4.7) | 0.529 |
| Fat free mass, Kg | 39.9(8.9) | 43.7(8.3) | 44.3(8.3) | 0.601 |
| SBP, mmHg | 135.2(14.1) | 132.4(19.7) | 129.7(12.1) | 0.574 |
| DBP, mmHg | 75.2(10.1) | 77.7(9.7) | 70.8(7.8) | 0.114 |
| MAP, mmHg | 95.2(10.5) | 95.9(12.4) | 90.5(8.7) | 0.276 |
| Glucose, mg/dl | 89.8(11.9) | 97.2(29.5) | 95.4(12.2) | 0.548 |
| HbA1c, % | 5.4(0.4) | 5.8(0.8) | 5.4(0.3) | 0.096 |
| Total colesterol, mg/dl | 185.2(26.9) | 190.4(34.0) | 191.0(23.7) | 0.669 |
| HDL, mg/dl | 53.5(19.7) | 56.7(12.2) | 54.9(8.8) | 0.709 |
| LDL, mg/dl | 109.23(24.7) | 116.9(27.0) | 120.9(18.9) | 0.334 |
| TG, mg/dl | 113.2(35.9) | 119.4(44.2) | 119.2(62.8) | 0.980 |
| hsCRP, mg/dl | 0.32(0.4) | 0.46(0.4) | 0.15(0.1) | 0.144 |
| Insulin, mUI/l | 12.8(8.7) | 16.5(13.1) | 8.8(3.5) | 0.126 |
| Peptide C, ng/ml | 2.0(0.9) | 1.9(0.9) | 2.0(0.5) | 0.751 |
| HOMA-IR | 1.65(1.1) | 2.12(1.6) | 1.10(0.4) | 0.098 |
| Central obesity (37) | 11 | 13 | 13 | 0.312# |
| Raised blood pressure (24) | 8 | 10 | 6 | 0.377# |
| Dyslipidemia (20) | 12 | 6 | 2 | |
| Raised fasting plasma glucose (FPG) (8) | 2 | 3 | 3 | 1.00£ |
| Reduced HDL (12) | 6 | 2 | 4 | 0.236# |
| Raised TG (7) | 2 | 2 | 3 | 1.00£ |
| BMI obesity (18) | 7 | 6 | 5 | 0.446# |
| Diabetes Melitus T2 (5) | 1 | 2 | 2 | 1.00£ |
Periodization of strength training.
| Weeks | Intensity (Borg CR-10) | Repetitions |
| 1 and 2 | 2 | 15 |
| 3–5 | 3 | 12–15 |
| 6–10 | 4 | 10–12 |
| 11–12 | 5 | 8–10 |
FIGURE 2Illustrative scheme of exercise intervention across groups.
Differences between pre- and post-intervention and between groups of the morphological and hemodynamic outcomes calculated with two-way analyses of variance (ANOVA) for repeated measures.
| RT+MICT ( | ES | RT+HIIT ( | ES | CON ( | ES | Observed Power within group | Observed Power between groups | |||||
| BM | −0.724(0.5) | 0.216 | –0.05 | −1.16(0.6) | 0.085 | –0.08 | 0.340(0.6) | 0.558 | 0.01 | 0.418 | 0.249 | 0.349 |
| BMI, kg/m2 | −0.16(0.5) | 0.749 | –0.03 | −0.44(0.2) | 0.145 | –0.08 | 0.05(0.1) | 0.588 | 0.02 | 0.354 | 0.150 | 0.130 |
| WC, cm | −3.61(1.3) | –0.31 | −4.80(1.2) | –0.32 | −2.61(1.5) | 0.111 | –0.35 | 0.716 | 0.994 | 0.147 | ||
| FM, % | −0.03(0.3) | 0.924 | 0.01 | −0.46(0.6) | 0.480 | –0.07 | 0.26(0.3) | 0.413 | 0.04 | 0.922 | 0.055 | 0.157 |
| FM, kg | −0.48(0.4) | 0.335 | –0.07 | −0.51(0.6) | 0.436 | –0.05 | 0.24(0.2) | 0.279 | 0.05 | 0.531 | 0.139 | 0.173 |
| FFM, kg | 0.66(1.0) | 0.519 | 0.08 | −0.93(0.5) | 0.114 | –0.11 | −0.21(0.2) | 0.431 | –0.03 | 0.445 | 0.445 | 0.236 |
| SBP, mmHg | −3.96(3.7) | 0.312 | –0.34 | 2.65(6.2) | 0.679 | 0.15 | 2.46(3.7) | 0.520 | 0.20 | 0.846 | 0.052 | 0.148 |
| DBP, mmHg | −0.38(1.9) | 0.849 | –0.04 | −1.42(2.5) | 0.590 | –0.15 | 3.2(2.7) | 0.255 | 0.43 | 0.576 | 0.063 | 0.212 |
| MAP, mmHg | −1.57(2.1) | 0.486 | –0.18 | −0.06(3.6) | 0.986 | –0.01 | 3.00(2.7) | 0.294 | 0.36 | 0.790 | 0.058 | 0.148 |
| Glucose, mg/dl | −1.53(2.2) | 0.512 | –0.12 | −5.00(1.7) | –0.17 | −0.23(2.4) | 0.925 | 0.09 | 0.704 | 0.287 | 0.373 | |
| HbA1c, % | −0.06(0.6) | 0.312 | 0.14 | −0.07(0.5) | 0.201 | –0.09 | 0.02(0.3) | 0.553 | –0.16 | 0.091 | 0.092 | 0.371 |
| TC, mg/dl | −2.53.(7.4) | 0.738 | –0.10 | −7.69(9.2) | 0.422 | –0.25 | −1.23(7.3) | 0.870 | –0.05 | 0.393 | 0.126 | 0.076 |
| HDL, mg/dl | −4.15(2.1) | 0.072 | –0.23 | −2.53(1.5) | 0.116 | –0.20 | −0.53(1.5) | 0.762 | –0.06 | 0.730 | 0.642 | 0.223 |
| LDL, mg/dl | 4.92(6.4) | 0.393 | 0.20 | −14.00(5.7) | –0.55 | −12.15(4.9) | –0.29 | 0.847 | 0.565 | 0.610 | ||
| TG, mg/dl | −17.61(8.2) | 0.55 | 9.00(10.5) | 0.566 | 0.18 | 28.23(15.5) | 0.077 | 0.24 | 0.534 | 0.565 | 0.610 | |
| hsCRP, mg/dl | −0.14(0.1) | 0.155 | –0.46 | −0.03(0.1) | 0.814 | –0.06 | 0.01(0.1) | 0.560 | 0.08 | 0.328 | 0.109 | 0.420 |
| Insulin, mUI/l | −0.34(1.6) | 0.858 | –0.04 | −2.12(0.8) | –0.16 | 0.59(1.5) | 0.754 | 0.12 | 0.239 | 0.055 | 0.319 | |
| Peptide C, ng/ml | −0.25(0.1) | 0.080 | –0.28 | −0.16(0.1) | 0.193 | –0.18 | 0.12(0.2) | 0.638 | 0.14 | 0.164 | 0.050 | 0.799 |
| HOMA-IR | −0.05(0.2) | 0.824 | –0.04 | −0.28(0.1) | –0.18 | 0.07(0.2) | 0.729 | 0.13 | 0.288 | 0.077 | 0.310 |